Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

NCT04150640 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT04150640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Recruiting
Start date
July 13, 2020
Completion date
May 31, 2028
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma